DNX Biopharmaceuticals Announces Collaboration with Lung Cancer Initiative at Johnson & Johnson
19 February 2020 - 2:00AM
JCN Newswire (English)
SAN DIEGO, CA, Feb 19, 2020 - (ACN Newswire) - DNX
Biopharmaceuticals, a biopharmaceutical company developing
long-acting therapeutic proteins for the treatment of patients with
life-long diseases and a resident of Johnson & Johnson
Innovation - JLABS @ Shanghai, announced today that it has entered
into a strategic collaboration with the Lung Cancer Initiative at
Johnson & Johnson*. Under terms of the agreement, the Lung
Cancer Initiative has taken an exclusive license to research,
develop and commercialize novel molecules from within the DNX
portfolio. Financial terms of the collaboration were not
disclosed.
"We are delighted to be collaborating with the Lung Cancer
Initiative at Johnson & Johnson," said Rajiv Datar, Ph.D.,
co-founder and CEO of DNX. "We look forward to progressing DNX's
novel molecules into clinical development."
"Our collaboration with the Lung Cancer Initiative at Johnson &
Johnson was fostered by being an awardee of the Lung Cancer
Innovation QuickFire Challenge and receiving residency at Johnson
& Johnson Innovation - JLABS, Shanghai," commented Dr. Carl
Edwards III, CSO of DNX. "We are now looking forward to
establishing our Asia-Pacific Research and Development capabilities
in Shanghai, which will be wholly dedicated to Cancer
Immunotherapy."
About DNX Biopharmaceuticals, Inc.
Founded in 2014 and headquartered in San Diego, California, USA,
DNX is a biopharmaceutical company developing non-immunogenic,
long-acting biologic therapies for the treatment of patients with
life-long diseases linked to inflammation, autoinflammation and
oncology. As an awardee of the Lung Cancer Innovation QuickFire
Challenge, DNX received residency at Johnson & Johnson
Innovation - JLABS @ Shanghai. At JLABS in Shanghai, DNX will
pursue an ongoing R&D effort that leverages its intrinsically
disordered protein technologies designed to explore the tumor
microenvironment, leading to the identification of novel pathways
that can be targeted with molecules to substantially influence
"anti-tumoral" therapeutic responses. Ongoing nonclinical efforts
have identified several novel candidates that may act as "Immune
Checkpoint Inhibitors" alone or in combination with existing
standard of care anti-PD-1 and CTLA-4 therapies to reverse CD8+ T
cell functions, all with the aim of improving clinical outcomes
across the vast range of cancer conditions. For more information,
please visit www.dnxbio.com.
*Johnson & Johnson Enterprise Innovation Inc. is the legal
entity to the agreement.
Media Contact:
Claude Gingras, CFO
Claude.Gingras@dnxbio.com
Related Links
- J&J Announcement of the Winners of the Lung Cancer QuickFire
Award
https://www.newsfilecorp.com/redirect/XmpnIyDP
To view the source version of this press release, please visit
https://www.newsfilecorp.com/release/52493
Source: DNX Biopharmaceuticals
Copyright 2020 ACN Newswire . All rights reserved. |
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to May 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2023 to May 2024